Javelin Biotech specializes in advancing preclinical drug discovery through innovative technologies that enhance the understanding of drug interactions with human physiology. Their platform integrates human tissue chips and AI-enabled digital twin technology, which collectively provide a more accurate and human-relevant approach to drug testing. The human tissue chips are designed to replicate the complexity and specificity of human biology, generating high-content data that is crucial for assessing drug efficacy and safety. This approach addresses the limitations of traditional animal models and simplistic in vitro systems, ultimately aiming to reduce the costs and risks associated with preclinical drug development.

One of the key offerings from Javelin Biotech is the Liver Tissue Chip (LTC) platform, which utilizes human microphysiological systems (MPS) to predict drug behavior in humans well before clinical trials commence. The LTC platform supports long-term culture of metabolically active human liver cells, allowing for the simultaneous assessment of various clinical biomarkers and drug responses. This technology not only enhances the reliability of preclinical testing but also facilitates the development of novel assays tailored to specific research needs. By leveraging machine learning algorithms within their digital twin software, Javelin Biotech provides researchers with tools to design experiments and analyze data efficiently, thereby accelerating the lead optimization process in drug development.

United States

Javelin Biotech makes predictive drug discovery platforms that merge human biology with computational biology to improve the speed and predictive power of preclinical testing. The Javelin platform combines human tissue chips, also known as organs-on-chip, with translational software to provide predictive solutions for drug discovery.

Javelin Biotech

Company Details